Results 261 to 270 of about 45,883 (301)
Some of the next articles are maybe not open access.

Immunophenotype of Vestibular Schwannomas

Otology & Neurotology, 2020
Background: Vestibular schwannomas exhibit a uniquely variable natural history of growth, stability, or even spontaneous regression. We hypothesized that a transitory population of immune cells, or immunomodulation of tumors cells, may influence the growth pattern of schwannomas.
Wenya Linda, Bi   +8 more
openaire   +2 more sources

Immunophenotyping of aneuploid cells

Cancer Genetics and Cytogenetics, 1989
This review article describes the MAC and MACISH (morphology, antibody, chromosomes, in situ hybridization) methods, which allow the examination of numerical chromosome abnormalities of morphologically and immunologically classified interphase or mitotic cells.
S, Knuutila, L, Teerenhovi
openaire   +2 more sources

Immunophenotype of Myxopapillary Ependymomas

Applied Immunohistochemistry & Molecular Morphology, 2013
Myxopapillary ependymoma (MPE) is a slow-growing tumor occurring almost exclusively in the region of conus medullaris, cauda equina, and filum terminale. On microscopic examination, some of these tumors show solid sheets of cells with an epithelioid morphology mimicking a metastatic carcinoma.
Ihab, Lamzabi   +4 more
openaire   +2 more sources

The immunophenotype of pituitary adenomas

Endocrine Pathology, 1996
Although the production of pituitary hormones by adenohypophysial tumors has been studied extensively, an examination of the immunophenotype of pituitary adenomas using a broad spectrum of antibodies has not been previously investigated. We studied 23 pituitary adenomas using a large panel of antibodies to determine if these tumors exhibited a common ...
Ricardo V., Lloyd   +3 more
openaire   +2 more sources

Immunophenotyping of Chronic Lymphocytic Leukemia

Clinical Laboratory, 2017
Chronic Lymphocytic Leukemia (CLL) is one of the most common diagnoses made by flow cytometry laboratories. There is no consensus on which markers need to be used in flow cytometry for accurate immunophenotyping. Herein, we investigated the role of markers used in flow cytometry in the distinction between CLL and MCL.A total 339 recently diagnosed B ...
Falay, Mesude, Ozet, GÜLSÜM
openaire   +3 more sources

In the realm for standardization in immunophenotyping

Cytometry Part A, 2012
STANDARDIZATION and quality control is the keystone of reliable and trustworthy diagnosis. This is particularly true for cellular diagnostics where the preanalytics, instrumentation, and reagents are very diverse and prone to innumerable variations affecting the results (1). Furthermore, as critical are the objects of interest—the cells from biological
openaire   +2 more sources

Immunophenotyping of Plasma Cells

Current Protocols in Cytometry, 2006
AbstractPlasma cell enumeration and immunophenotyping has been shown to be of value in predicting the outcome for patients with myeloma. Detection of abnormal plasma cells at a leukocyte level >0.01% at the end of therapy predicts early relapse. Although clonally related populations at varying stages of differentiation are reported to be present in ...
openaire   +2 more sources

Cytogenetics and Immunophenotype

Leukemia & Lymphoma, 1994
C, Mecucci, H, van den Berghe
openaire   +2 more sources

Immunophenotyping by Mass Cytometry

2019
Mass cytometry is a novel technology similar to flow cytometry in which antibodies are tagged with heavy metal molecules rather than fluorophores and then detected with time-of-flight mass spectrometry. This enables measurement of up to 50 simultaneous parameters with no autofluorescent background and little or no spillover or required compensation ...
openaire   +2 more sources

B-Cell Immunophenotyping

2004
Publisher Summary B-lymphocytes provide the humoral (antibody-mediated) arm of the adaptive immune system. Like all leukocytes, B cells develop from hematopoietic stem cells in the bone marrow. The bone marrow is a tissue where B cells of all developmental stages can be isolated.
openaire   +2 more sources

Home - About - Disclaimer - Privacy